Patient Characteristics at Baseline
| Characteristic | Placebo-First Arm (n = 17) | Nifedipine-First Arm (n = 15) |
|---|---|---|
| Age, mean, y | 50 | 59 |
| Sex | ||
| Women, No. | 8 | 10 |
| Men, No. | 9 | 5 |
| Chilblain symptoms | ||
| Mean duration at intake, wk | 7 | 6 |
| Experiencing first episode, No. | 2 | 2 |
| Experienced >1 episode, No. | 4 | 4 |
| Experiences episode every year, No. | 12 | 10 |
| Mean VOC score, mma,b | 25 | 24 |
| Mean VOD score, mmb | 17 | 15 |
| Smoking, No. | 3 | 3 |
| Comorbidity | ||
| Diabetes, No. | 0 | 1 |
| Peripheral arterial disease, No. | 1 | 0 |
| Raynaud phenomenon, No. | 6 | 3 |
| Relevant medication use | ||
| β-blocker, No. | 0 | 0 |
| Nicotine replacement drug, No. | 0 | 0 |
| Acetylsalicylic acid, No. | 0 | 1 |
| ACE or angiotensin II receptor blocker, No. | 3 | 2 |
ACE = angiotensin-converting enzyme; VOC = visual analogue scale on complaints; VOD = visual analogue scale on disability.
↵a The higher of either the visual analogue scale itch score or the visual analogue scale pain score.
↵b Scores measured on 100-mm scales where higher values indicate more complaints (symptoms) or greater disability.